Etanercept biosimilar associated with Guillain-Barr é syndrome: insights from a case.

Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo. 2019 Jul 09;71(2):99-102 Authors: Shobha V, Desai AM, Matthew T Abstract Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far. PMID: 31309782 [PubMed - in process]
Source: Reumatismo - Category: Rheumatology Authors: Tags: Reumatismo Source Type: research